Group 1 - The company's stock price closed at 14.58 yuan on August 25, with a decrease of 0.02 yuan, representing a decline of 0.14% [1] - The trading volume on that day was 116,300 hands, with a transaction amount of 169 million yuan [1] - The company operates in the chemical pharmaceutical industry, focusing on the research, production, and sales of chemical raw materials and pharmaceutical intermediates [1] Group 2 - On August 25, the company announced that its isosorbide mononitrate tablets received a drug registration certificate from the National Medical Products Administration [1] - This medication is indicated for the long-term treatment of coronary heart disease and the prevention of angina pectoris [1] Group 3 - On August 25, the net outflow of main funds was 16.39 million yuan, accounting for 0.44% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow of main funds reached 38.2 million yuan, representing 1.02% of the circulating market value [1]

Core Viewpoint - Rundu Co., Ltd. has received a drug registration certificate from the National Medical Products Administration for Isosorbide Mononitrate Tablets, which are indicated for the long-term treatment of coronary heart disease, prevention of angina pectoris, treatment of persistent angina after myocardial infarction, and treatment of chronic congestive heart failure in combination with digoxin and/or diuretics [2]. Company Summary - The drug Isosorbide Mononitrate Tablets is specifically designed for the long-term management of coronary heart disease and related conditions [2]. - The approval of this drug may enhance the company's product portfolio and market presence in the cardiovascular treatment segment [2].

Core Viewpoint - Rundu Co., Ltd. has received a drug registration certificate from the National Medical Products Administration for Isosorbide Mononitrate Tablets, which are indicated for the long-term treatment of coronary heart disease, prevention of angina pectoris, treatment of persistent angina after myocardial infarction, and treatment of chronic congestive heart failure in combination with digoxin and/or diuretics [1] Company Summary - Rundu Co., Ltd. has announced the receipt of a drug registration certificate for Isosorbide Mononitrate Tablets [1] - The drug is specifically indicated for multiple cardiovascular conditions, including coronary heart disease and chronic congestive heart failure [1] Industry Summary - The approval of Isosorbide Mononitrate Tablets highlights the ongoing development and regulatory progress within the cardiovascular drug market [1] - The drug's indications suggest a focus on addressing significant health issues related to heart diseases, which are prevalent in the healthcare sector [1]

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 珠海润都制药股份有限公司（以下简称"公司"或"本公司"）近日收到国 家药品监督管理局签发的《药品注册证书》。现将有关情况公告如下： 一、药品基本情况 药品名称：单硝酸异山梨酯片（以下简称"本品"） 剂型：片剂 申请事项：药品注册(境内生产) 规格：10mg 证券代码：002923 证券简称：润都股份 公告编号：2025-037 珠海润都制药股份有限公司 关于单硝酸异山梨酯片获得药品注册证书的公告 注册分类：化学药品4类 受理号：CYHS2401415 证书编号：2025S02527 药品批准文号：国药准字H20255160 药品注册标准编号：YBH19702025 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及生产工艺照所附执行。 二、药品的适应症 本品适用于冠心病的长期治疗；心绞痛的预防；心肌梗死后持续心绞痛的治 疗；与洋地黄和/或利尿剂联合应用，治疗慢性充血性心力衰竭。 三、对公司的影响及风险提示 公司高度重视 ...

证券时报·数据宝统计，截至发稿，润都股份收盘价为14.60元，下跌0.48%，本期筹码集中以来股价累 计下跌3.12%。具体到各交易日，4次上涨，6次下跌。 润都股份8月22日披露，截至8月20日公司股东户数为29358户，较上期（8月10日）减少5489户，环比降 幅为15.75%。 7月15日公司发布上半年业绩预告，预计实现净利润-3900.00万元至-3000.00万元，变动区间 为-203.17%~-179.36%。（数据宝） 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 （文章来源：证券时报网） 公司发布的一季报数据显示，一季度公司共实现营业收入2.55亿元，同比下降16.79%，实现净利润 186.82万元，同比下降93.57%，基本每股收益为0.0100元，加权平均净资产收益率0.16%。 ...

Group 1 - The company, Zhuhai Runduo Pharmaceutical Co., Ltd., has received the approval notice for the listing application of hydrochlorothiazide as a chemical raw material drug from the National Medical Products Administration [1][2] - The drug hydrochlorothiazide is indicated for conditions such as edema, hypertension, central or renal diabetes insipidus, and nephrolithiasis [3] - The approval of this drug enhances the company's product portfolio and strengthens its full industry chain layout, positively impacting future operational performance [3] Group 2 - The application for the drug was submitted in April 2024, with the approval process involving additional research and documentation submitted in 2025 [2] - The approval is based on compliance with the relevant requirements of the Drug Administration Law of the People's Republic of China [1]

Group 1 - The company, Zhuhai Runduo Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the listing application of hydrochlorothiazide as a chemical raw material drug [1] - The approval enhances the company's product portfolio and improves its competitiveness in the market, which is expected to have a positive impact on future operating performance [1] - The drug is indicated for conditions such as edema, hypertension, central or renal diabetes insipidus, and kidney stones [1] Group 2 - The approval process included a supplementary research notification received in January 2025, with the company completing the required work and submitting documentation by May 2025, leading to the final approval in August 2025 [1] - The registration number for the drug is Y20240000290, and the notification number is 2025YS00718 [1]

Group 1 - The core point of the article is that Rundu Co., Ltd. has received approval from the National Medical Products Administration for the listing application of hydrochlorothiazide as a chemical raw material drug [2] Group 2 - The announcement was made on the evening of August 19, indicating a significant regulatory milestone for the company [2] - The approval is expected to enhance the company's product portfolio and market position in the pharmaceutical industry [2]

Core Viewpoint - Rundu Co., Ltd. has received approval from the National Medical Products Administration for the listing application of hydrochlorothiazide, which is expected to enhance the company's product portfolio and market competitiveness, positively impacting future operating performance [1]. Group 1 - The approval of hydrochlorothiazide is applicable for treating edema-related diseases, hypertension, central or renal diabetes insipidus, and nephrolithiasis [1]. - This approval enriches the company's product categories and improves its full industry chain layout [1]. - The development is anticipated to strengthen the company's market competitiveness [1].

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 珠海润都制药股份有限公司（以下简称"公司"）近日收到国家药品监督管 理局签发的关于氢氯噻嗪（以下简称："本品"）《化学原料药上市申请批准通 知书》。现将有关情况公告如下： 证券代码：002923 证券简称：润都股份 公告编号：2025-036 珠海润都制药股份有限公司 关于氢氯噻嗪获得化学原料药上市申请批准通知书的公告 一、药品基本情况 1、药品基本信息 原料药名称：氢氯噻嗪 受理号：CYHS2460314 登记号：Y20240000290 通知书编号：2025YS00718 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执行。 2、其他相关情况 2024年4月，公司向国家药品监督管理局药品审评中心（CDE）递交氢氯噻嗪 境内生产化学原料药上市申请注册申报资料并获受理，2025年1月收到CDE发出的 补充研究通知，2025年5月，公司完成补充研究工作并递交资料，2025年8月获得 《化学原料药上市申请批准通知书》。 二、对公司的 ...